CClinicalTrials.gg
CompletedNCT03807648Updated Feb 12, 2020

I USE LR in the ED

An observational study in Kidney Injury, sponsored by Intermountain Health Care, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Intermountain Health Care, Inc. · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200,000
Ages
18 Years and older
Sex
All
01

Study summary

To study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.

02

Conditions studied

  • Kidney Injury
03

In context

Lead sponsor

Intermountain Health Care, Inc. is the lead sponsor of 118 studies on the registry; 15 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Data to determine study outcomes will be extracted from the EDW and stored in a secure database. No actualy contact with patients will take place for this data-only study

Inclusion criteria

  • Adult patients (≥18 years) receiving a minimum of 1000ml of intravenous fluids starting in the emergency department per standard of care

Exclusion criteria

Exclusion Criteria:

  • Patients aged ≤17 years
  • Previously enrolled patients with >1 ED admission within the 30-day follow-up period
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200,000 participants (actual)
Patient registry
No

Interventions

  • OtherData Inclusion

    Patients in this group will be included in the project

06

What researchers measure

Primary outcomes

  1. Number of participants with major Adverse Kidney Events

    death from any cause, new renal replacement therapy or persistent renal dysfunction

    Time frame: within 30 days or at hospital discharge

  2. LR IV Fluids administered

    Proportion of LR IV fluids following implementation

    Time frame: Through study completion (an average of 1 year)

Secondary outcomes

  1. Rate of hospital admission and readmission

    Time frame: Within 30 days of initial ED encounter

  2. Cost

    Direct costs of ED care and hospitalization

    Time frame: Through study completion (an average of 1 year)

07

Study locations

1 site
  • Intermountain Medical Center
    Murray, Utah 84157-7000, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03807648
Lead sponsor
Intermountain Health Care, Inc.
Responsible party
Sponsor
First posted
Jan 17, 2019
Start date
Dec 20, 2018
Primary completion
Dec 31, 2019
Completion
Jan 31, 2020
Last update
Feb 12, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion